Cargando…

FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay

Previous reports demonstrated that FLU-v, a peptide-based broad-spectrum influenza vaccine candidate, induced antibody and cellular immune responses in humans. Here, we evaluate cellular effector functions and cross-reactivity. PBMC sampled pre- (day 0) and post-vaccination (days 42 and 180) from va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oftung, Fredrik, Næss, Lisbeth M., Laake, Ida, Stoloff, Gregory, Pleguezuelos, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505334/ https://www.ncbi.nlm.nih.gov/pubmed/36146606 http://dx.doi.org/10.3390/vaccines10091528

Ejemplares similares

Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial
por: van Doorn, Eva, et al.
Publicado: (2017)

Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease
por: Nowacki, Tobias M., et al.
Publicado: (2012)

The Granzyme B ELISPOT assay: an alternative to the (51)Cr-release assay for monitoring cell-mediated cytotoxicity
por: Shafer-Weaver, Kimberly, et al.
Publicado: (2003)

An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity
por: Barabas, Sascha, et al.
Publicado: (2017)

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
por: Janetzki, Sylvia, et al.
Publicado: (2009)

Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
por: Maecker, Holden T, et al.
Publicado: (2008)

Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study
por: Pleguezuelos, Olga, et al.
Publicado: (2020)

Potential Role of M. tuberculosis Specific IFN-γ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis
por: Chiappini, Elena, et al.
Publicado: (2012)

Determining the Latent Tuberculosis Infection by IFN - γ Elispot Assay in Healthcare Workers From University Hospitals of Shiraz, South West of Iran
por: Taheri, Mohammad, et al.
Publicado: (2013)

Comparative Multi-Donor Study of IFNγ Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays
por: Hagen, Jodi, et al.
Publicado: (2015)

Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005)

Changes in Cell-Mediated Immunity (IFN-γ and Granzyme B) Following Influenza Vaccination
por: Otani, Naruhito, et al.
Publicado: (2021)

Increased Level of IFN-γ and IL-4 Spot-Forming Cells on ELISPOT Assay as Biomarkers for Acute Graft-Versus-Host Disease and Concurrent Infections
por: Hirayama, Masahiro, et al.
Publicado: (2012)

Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation
por: Wagner-Drouet, Eva, et al.
Publicado: (2021)

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium
por: Waerlop, Gwenn, et al.
Publicado: (2022)

Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot
por: Thümmler, Laura, et al.
Publicado: (2021)

Reversion and conversion of Mycobacterium tuberculosis IFN-γ ELISpot results during anti-tuberculous treatment in HIV-infected children
por: Connell, Tom G, et al.
Publicado: (2010)

Response definition criteria for ELISPOT assays revisited
por: Moodie, Z., et al.
Publicado: (2010)

Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis
por: Santos, Radleigh, et al.
Publicado: (2014)

Pretransplant Donor-specific IFNγ ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis
por: Montero, Nuria, et al.
Publicado: (2019)

Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates
por: Yang, Fan, et al.
Publicado: (2021)

ELISPOT Cell Analysis Assay: Searching for Extracellular Footprints
por: Kalyuzhny, Alexander E.
Publicado: (2011)

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
por: Mander, A., et al.
Publicado: (2010)

Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method
por: Patton, Kathryn S., et al.
Publicado: (2021)

Enteric bacteria induce IFNγ and Granzyme B from human colonic Group 1 Innate Lymphoid Cells
por: Castleman, Moriah J., et al.
Publicado: (2019)

CD8(+) Granzyme B(+)–Mediated Tissue Injury vs. CD4(+)IFNγ(+)–Mediated Parasite Killing in Human Cutaneous Leishmaniasis
por: Santos, Claire da Silva, et al.
Publicado: (2013)

ELISPOT assays and their diagnostic potential in Lyme disease and Lyme neuroborreliosis
por: Ettischer‐Schmid, N., et al.
Publicado: (2020)

Utility of interferon-γ ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa
por: Lawn, Stephen D, et al.
Publicado: (2007)

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories
por: Gill, Dilbinder K., et al.
Publicado: (2010)

Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation
por: Zitzner, Jennifer R., et al.
Publicado: (2012)

Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT
por: Anthony, Donald D., et al.
Publicado: (2012)

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays
por: Janetzki, Sylvia, et al.
Publicado: (2014)

Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation
por: Pleguezuelos, Olga, et al.
Publicado: (2013)

IFN-γ-Based ELISpot as a New Tool to Detect Human Infections with Borna Disease Virus 1 (BoDV-1): A Pilot Study
por: Eidenschink, Lisa, et al.
Publicado: (2023)

Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy
por: Savic, Miloje, et al.
Publicado: (2017)

Mobilization permits reliable ELISPOT detection of long-term memory T cells secreting IFN-γ, IL-4, IL-5, and IL-17 without in vitro expansion
por: Ghosh, Jaya, et al.
Publicado: (2013)

Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and Fluorospot assay
por: Janetzki, Sylvia
Publicado: (2015)

Flu Virus Attenuates Memory Clearance of Pneumococcus via IFN-γ-Dependent Th17 and Independent Antibody Mechanisms
por: Li, Ning, et al.
Publicado: (2020)

Comparison of ELISpot and FluoroSpot in the Analysis of Swine Flu-Specific IgG and IgA Secretion by in Vivo Activated Human B Cells
por: Kesa, Gun, et al.
Publicado: (2012)

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
por: Shafer-Weaver, Kimberly A, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_c0fa47ml2khld08drhpqsuneqt